Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.28)
# 432
Out of 4,981 analysts
239
Total ratings
42.53%
Success rate
21.03%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $30.31 | +246.42% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $61.11 | +93.09% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $49.48 | +49.56% | 2 | Aug 27, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $42 → $46 | $45.47 | +1.17% | 3 | Aug 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $23 → $32 | $37.96 | -15.70% | 8 | Aug 6, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $5.40 | +103.70% | 1 | Jul 24, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $25 → $29 | $7.75 | +274.19% | 3 | Jul 10, 2025 | |
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $5.39 | +196.85% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $7.02 | +42.45% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $6.36 | +371.70% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $17.39 | +365.78% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.07 | +128.01% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $53.62 | +129.39% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.26 | +2,660.74% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.85 | +278.38% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $59.80 | +120.74% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $16.11 | +55.18% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $24.44 | +174.20% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $7.99 | +162.83% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $8.07 | +259.36% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $5.05 | +236.63% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.84 | +181.69% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $16.49 | +251.84% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.43 | +352.67% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $6.43 | +179.94% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $4.25 | +229.41% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.47 | +784.35% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.63 | +1,188.34% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.34 | +347.76% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.04 | +1,823.08% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.82 | +502.09% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.58 | +56,862.03% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $2.87 | +13,837.28% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.93 | +9,005.52% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.93 | +2,497.40% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.01 | +5,880.07% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.07 | +928.04% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.95 | +6,185.36% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.26 | +7,042.86% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.51 | +166,787.42% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.47 | +33,605.50% | 1 | Jan 9, 2020 |
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $30.31
Upside: +246.42%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $61.11
Upside: +93.09%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $49.48
Upside: +49.56%
Supernus Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $42 → $46
Current: $45.47
Upside: +1.17%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23 → $32
Current: $37.96
Upside: -15.70%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.40
Upside: +103.70%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $7.75
Upside: +274.19%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.39
Upside: +196.85%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $7.02
Upside: +42.45%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.36
Upside: +371.70%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $17.39
Upside: +365.78%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $3.07
Upside: +128.01%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $53.62
Upside: +129.39%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.26
Upside: +2,660.74%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.85
Upside: +278.38%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $59.80
Upside: +120.74%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $16.11
Upside: +55.18%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $24.44
Upside: +174.20%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $7.99
Upside: +162.83%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $8.07
Upside: +259.36%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $5.05
Upside: +236.63%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.84
Upside: +181.69%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $16.49
Upside: +251.84%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.43
Upside: +352.67%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $6.43
Upside: +179.94%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $4.25
Upside: +229.41%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.47
Upside: +784.35%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.63
Upside: +1,188.34%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.34
Upside: +347.76%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.04
Upside: +1,823.08%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.82
Upside: +502.09%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.58
Upside: +56,862.03%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $2.87
Upside: +13,837.28%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.93
Upside: +9,005.52%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.93
Upside: +2,497.40%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $3.01
Upside: +5,880.07%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.07
Upside: +928.04%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $0.95
Upside: +6,185.36%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.26
Upside: +7,042.86%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.51
Upside: +166,787.42%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.47
Upside: +33,605.50%